You are here: Industry Insights > CAR-T

News List

Novartis’ slow-rolling Kymriah wins coverage in Japan at $305K: report fiercepharma
May 16, 2019
After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking med, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales.
Proposed guidelines for handling CAR-T cell side effects europeanpharmaceuticalreview
May 06, 2019
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects…
Medicare proposal will increase payments for CAR-T cell therapies Yescarta, Kymriah firstwordpharma
April 25, 2019
The US Centers for Medicare and Medicaid Services (CMS) issued a proposal that would see an increase in payments for CAR-T cell therapies ...
Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial fiercebiotech
April 23, 2019
Personalized CAR-T treatments for leukemia and lymphoma have offered new hope for patients with tough-to-treat disease, but the engineered cell therapies can cause a dangerous immune reaction called cytokine release syndrome (CRS).
Cell therapy rejected for aggressive adult lymphoma on the NHS europeanpharmaceuticalreview
April 18, 2019
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS…
Bringing CAR-T to solid tumors with help from alpacas fiercebiotech
April 17, 2019
CAR-T therapies made from individual patients’ immune cells have revolutionized the treatment of some blood cancers, but they’ve been difficult to translate to solid tumors.
Merck collaborates with GenScript to accelerate the industrialization of cellular and genetic therapies in China pharmafocusasia
March 20, 2019
Merck , a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotechnology company GenScript to form a strategic alliance with the aim of making plasmids and viral vectors.
French biotech Cellectis picks U.S. for commercial CAR-T production fiercepharma
March 13, 2019
Cellectis is building a 14,000-square-foot facility in Paris to produce clinical supplies...
SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma pharmatimes
March 12, 2019
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO pharmaphorum
March 07, 2019
It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-shelf’ cancer cell therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page